Pfizer Inc.
PFE
NYSE43.59
Pfizer Inc.
NYSE:PFE
RECENT
PRICE
43.59
P/E
RATIO
8.00
(PEG:0.06)
P/E RATIO
RELATIVE
TO S&P
0.36
DIV
YLD
3.27%
High:
Low:
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Legends
Stock price
0.63 Beta (1.0 Market)
0
0
0
0
0
0
0
0
0
% total return 02/23:
Stock
S&P
1y.
0
0
3y.
0
0
5y.
0
0
0
Percent shares traded:
0
0
0
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Fiscal year
6.68
2.67
2.15
0.96
7.00
1.18
1.66
1.15
7.18
1.20
2.46
1.27
7.14
1.23
2.20
0.79
8.44
1.03
1.24
0.76
8.63
1.28
2.38
0.80
7.93
1.96
2.11
0.88
7.57
3.23
2.39
0.97
7.82
1.44
2.41
1.04
7.91
1.13
2.11
1.12
8.68
1.18
2.28
1.20
8.80
3.57
2.39
1.28
9.14
1.90
2.32
1.36
9.29
2.92
1.79
1.44
7.54
1.73
2.09
1.52
14.51
3.92
5.33
1.56
17.77
5.31
4.17
1.59
Revenue per share
Earnings per share
Free Cash Flow per sh
Dividends per share
0.28
9.85
0.27
9.40
0.25
8.56
0.17
12.85
0.19
10.93
0.21
10.51
0.18
10.92
0.22
11.20
0.25
11.24
0.24
10.48
0.33
9.78
0.37
11.94
0.37
10.80
0.47
11.34
0.50
11.38
0.48
13.78
0.58
15.13
CAPEX per share
Book Value per share
7,242
6,917
6,727
7,007
8,036
7,817
7,442
6,813
6,346
6,176
6,089
5,970
5,872
5,569
5,555
5,601
5,608
Comm.Shares outs.(m)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
19.6
0.8
3.7%
12.9
0.5
3.8%
20.2
0.5
4.3%
10.7
0.4
3.7%
8.0
0.4
3.3%
Avg. annual P/E ratio
P/E relative to S&P500
Avg. annual div. yield
Capital Structure (2/10/22 | Q3)
Total liabilities
$102,459 m.
Total assets
$195,350 m.
Long-term debt
$31,653 m.
Cash and equiv.
$1,298 m.
Goodwill $49,441 m.
Retained earnings $122,967 m.
Common stock 5,607 m. shares
Market Capitalisation
$245,723 m. (as of 8/2/23)
67,425
27.0%
58,986
30.5%
51,584
31.7%
49,605
27.2%
48,851
26.6%
52,824
26.0%
52,546
26.8%
53,647
28.0%
51,750
26.9%
41,908
20.9%
81,288
24.9%
99,676
34.9%
Revenue (m)
Operating margin
9,026
10,009
7,611
14,570
6,410
22,003
5,537
9,135
5,157
6,960
5,757
7,215
6,269
21,308
6,384
11,153
6,010
16,273
4,777
9,616
5,191
21,979
4,822
29,771
Depreciation (m)
Net profit (m)
31.5%
14.8%
21.2%
24.7%
27.4%
42.7%
25.5%
18.4%
22.2%
14.2%
13.4%
13.7%
(73.5)%
40.6%
5.9%
20.8%
7.8%
31.4%
6.4%
22.9%
7.6%
27.0%
9.7%
29.7%
Income tax rate
Net profit margin
29,659
34,931
82,190
32,796
31,036
81,260
32,878
30,462
76,307
36,071
31,541
71,301
14,405
28,818
64,720
7,834
31,398
59,544
10,714
32,666
71,308
18,068
32,429
63,407
(4,501)
35,955
63,143
9,147
35,571
63,238
17,022
34,757
77,201
26,089
31,653
92,631
Working capital (m)
Long-term debt (m)
Equity (m)
6.7%
8.4%
12.2%
9.4%
10.1%
17.9%
13.6%
16.1%
28.8%
6.9%
8.1%
12.8%
5.7%
6.1%
10.8%
5.9%
5.6%
12.1%
16.6%
7.9%
29.9%
9.7%
8.3%
17.6%
13.6%
11.5%
25.8%
8.4%
7.5%
15.2%
16.8%
13.9%
28.5%
20.6%
17.7%
32.1%
ROIC
Return on capital
Return on equity
Working Capital
2019
2020
2021
Cash assets
9,830
10,309
10,469
Receivables
12,068
11,194
15,745
Inventory
8,283
8,046
9,059
Other
2,622
3,606
3,820
Current assets
32,803
35,067
59,693
Acc. Payable
4,220
4,309
5,578
Debt due
16,190
2,703
2,241
Other
16,894
18,908
34,852
Current liab.
37,304
25,920
42,671
37.7%
82.0%
55.2%
93.9%
70.1%
140.3%
27.7%
75.9%
0.3%
100.6%
(1.4)%
88.6%
64.1%
88.8%
28.5%
148.0%
50.6%
169.2%
12.2%
72.7%
60.3%
29.2%
70.1%
46.8%
Plowback ratio
Div.&Repurch. to FCF
Pfizer Inc. (US) started trading on January 1, 1944 (cik: 0000078003), operates in the Healthcare sector (Drug Manufacturers—General industry), has 79,000 full-time employees, and is led by Dr. Albert Bourla. Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Annual rates
(avg rate of change)
Past
5 y.
Past
10 y.
Revenues
18.38%
7.02%
Cash flow
35.59%
14.92%
Earnings
21.48%
28.18%
Dividends
3.33%
3.29%
Book value
2.68%
0.07%
Insider trading
Type
Shares
Date
Bourla Albert
Award
41
01/12/23
Damico Jennifer B.
Award
121
01/12/23
Johnson Rady A
Award
16
01/12/23
Echevarria Joseph
Award
903
12/30/22
Narayen Shantanu
Award
976
12/30/22
Fiscal Year Ends
Quarterly Revenue (m)
Full fiscal year
I
II
III
IV
2020
12,028
11,801
12,131
5,947
41,907
2021
14,582
18,977
24,094
23,635
81,288
2022
25,661
27,742
22,638
- -
- -
Fiscal Year Ends
Earnings per share
Full fiscal year
I
II
III
IV
2020
0.61
0.62
0.39
0.11
1.73
2021
0.87
0.99
1.45
0.61
3.92
2022
1.40
1.77
1.54
- -
- -
Fiscal Year Ends
Quarterly dividends paid
Full fiscal year
I
II
III
IV
2020
0.38
0.38
0.38
0.38
1.52
2021
0.39
0.39
0.39
0.39
1.56
2022
0.40
0.40
0.40
- -
- -
01/31/2023
Pfizer Expects Drop in Revenue as Vaccine Demand Wanes
The Wall Street Journal - Read more...
12/30/2022
Drugmakers Spent Freely in 2022 to Protect Revenue
The Wall Street Journal - Read more...
11/01/2022
Pfizer Raises Revenue Outlook on Higher-Than-Expected Covid Vaccine Sales
The Wall Street Journal - Read more...
11/01/2022
RSV Vaccine Protects Babies From Severe Infections, Pfizer Study Finds
The Wall Street Journal - Read more...
10/31/2022
Drugmakers Fight Over Lucrative Pneumonia Vaccines
The Wall Street Journal - Read more...
09/23/2022
Moderna Booster Shortage Sees Fewer Appointments
The Wall Street Journal - Read more...
09/05/2022
How Pfizer-BioNTech Modified Covid-19 Vaccines for Fall Boosters
The Wall Street Journal - Read more...
08/31/2022
Covid-19 Booster Shots Targeting Omicron Authorized
The Wall Street Journal - Read more...
08/28/2022
Covid Booster Rollout to Precede Human-Trial Data
The Wall Street Journal - Read more...
08/26/2022
Moderna Sues Pfizer and BioNTech Over mRNA Patents
The Wall Street Journal - Read more...
08/23/2022
Covid-19 Booster Campaign Expected to Launch Next Month
The Wall Street Journal - Read more...
08/22/2022
Pfizer, BioNTech Seek FDA Approval for Updated Covid-19 Vaccine
The Wall Street Journal - Read more...
08/05/2022
Pfizer in Advanced Talks to Buy Global Blood Therapeutics
The Wall Street Journal - Read more...
07/28/2022
Pfizer Sales Climb Again on Covid-19 Products
The Wall Street Journal - Read more...
07/26/2022
Drugmakers Hope New Heart Drugs Boost Sales, Revive Market
The Wall Street Journal - Read more...
07/08/2022
FDA Fully Approves Pfizer’s Covid-19 Vaccine for Adolescents
The Wall Street Journal - Read more...
06/30/2022
Pfizer Asks FDA to Fully Approve Its Covid-19 Pill
The Wall Street Journal - Read more...
06/29/2022
U.S. Agrees to Pay $3.2 Billion for More Pfizer Covid Vaccines
The Wall Street Journal - Read more...
06/25/2022
Pfizer’s Omicron-Targeting Covid-19 Vaccines Generate Stronger Immune Response
The Wall Street Journal - Read more...
06/18/2022
CDC Recommends Covid-19 Vaccines for Young Children
The Wall Street Journal - Read more...
06/15/2022
FDA Advisers Endorse Pfizer, Moderna Covid-19 Vaccines in Young Children
The Wall Street Journal - Read more...
06/12/2022
Pfizer Covid Vaccine Works Safely in Young Children
The Wall Street Journal - Read more...
06/01/2022
Pfizer Asks FDA to Authorize Its Covid-19 Vaccine for Children Under 5
The Wall Street Journal - Read more...
05/25/2022
Pfizer to Sell Vaccines, Drugs at Low Prices to Poorer Countries
The Wall Street Journal - Read more...
05/24/2022
Covid-19 Vaccine and Drug Sales, Once Booming, Plateau
The Wall Street Journal - Read more...
05/23/2022
Three Doses of Pfizer’s Covid-19 Vaccine 80% Effective in Young Children, Company Says
The Wall Street Journal - Read more...
05/19/2022
CDC Recommends Covid-19 Boosters for 5- to 11-Year-Olds
The Wall Street Journal - Read more...
05/17/2022
Pfizer’s Covid-19 Booster Cleared for 5- to 11-Year-Olds
The Wall Street Journal - Read more...
05/10/2022
Pfizer to Buy Rest of Biohaven for $11.6 Billion
The Wall Street Journal - Read more...
05/03/2022
Pfizer Sales Soar on Covid-19 Vaccine Sales
The Wall Street Journal - Read more...
04/29/2022
Pfizer’s Covid Pill Failed Study Testing Its Preventive Use
The Wall Street Journal - Read more...
04/07/2022
Pfizer to Buy ReViral for Up to $525 Million
The Wall Street Journal - Read more...
03/29/2022
FDA, CDC Endorse Second Covid-19 Booster Shot for Adults 50 and Over
The Wall Street Journal - Read more...
03/22/2022
Pfizer, Unicef Strike Covid-19 Pill Deal
The Wall Street Journal - Read more...
03/14/2022
Merck’s Covid-19 Pill Heavily Used So Far Despite Concerns
The Wall Street Journal - Read more...
03/01/2022
Pfizer’s Covid-19 Vaccine Protected Kids During Omicron Wave, CDC Study Finds
The Wall Street Journal - Read more...
02/19/2022
FDA Eyes Second Covid-19 Booster Shot
The Wall Street Journal - Read more...
02/18/2022
Lower Omicron Efficacy Led to FDA Delay on Pfizer Shot in Young Kids
The Wall Street Journal - Read more...
02/11/2022
FDA to Take More Time Reviewing Pfizer’s Covid-19 Vaccine in Young Children
The Wall Street Journal - Read more...
02/08/2022
Pfizer Forecasts $54 Billion in 2022 Sales From Covid Vaccine, Treatment
The Wall Street Journal - Read more...
02/08/2022
Peloton, Pfizer, Meta, General Motors: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
01/19/2022
SoFi, Bakkt, Bank of America, Cisco: What to Watch When the Stock Market Opens Today
The Wall Street Journal - Read more...
01/18/2022
Pfizer’s New Covid-19 Pill Works Against Omicron in Lab
The Wall Street Journal - Read more...
01/06/2022
CDC Recommends First Covid-19 Boosters for 12- to 15-Year-Olds
The Wall Street Journal - Read more...
01/04/2022
Apple, Ford, Jowell, Carnival: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
01/03/2022
FDA Authorizes Pfizer-BioNTech Booster for 12- to 15-Year-Olds
The Wall Street Journal - Read more...
12/29/2021
Drugmakers Battle Over Patents for Covid-19 Vaccines
The Wall Street Journal - Read more...
12/22/2021
Pfizer’s Covid-19 Pill Is Authorized in U.S.
The Wall Street Journal - Read more...
12/20/2021
Pandemic Trades Roar Back: What to Watch in the Stock Market Today
The Wall Street Journal - Read more...
12/17/2021
Pfizer Delays Plans to Seek Authorization of Covid-19 Vaccine for Young Children
The Wall Street Journal - Read more...